T4	total-participants 316 339	One hundred ninety-four
T5	eligibility 340 414	patients with histologically proven primary node-negative breast carcinoma
T7	intervention-participants 474 476	98
T8	control-participants 524 526	96
T9	outcome 584 592	relapses
T10	outcome 600 606	deaths
T11	outcome 626 663	relapse-free survival rate at 7 years
T12	iv-bin-percent 689 692	93%
T13	cv-bin-percent 701 704	81%
T14	outcome 1105 1137	overall survival rate at 7 years
T15	outcome 777 793	stage T2 disease
T16	iv-bin-percent 795 799	100%
T17	cv-bin-percent 827 830	64%
T18	outcome 863 900	younger and/or premenopausal patients
T19	iv-bin-percent 933 937	100%
T20	cv-bin-percent 963 966	81%
T21	outcome 1001 1032	patients > or = 50 years of age
T22	iv-bin-percent 1034 1037	90%
T23	cv-bin-percent 1063 1066	82%
T24	control 0 42	High-dose oral medroxyprogesterone acetate
T25	intervention 46 55	tamoxifen
